The Center for Biosimilars® recaps the top stories for the year 2019.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the year 2019.
Number 5: In January, Pfizer confirmed that it made the decision to terminate 5 preclinical biosimilar programs after the results of the company’s annual investment review.
Number 4: Also in January, the FDA approved Samsung Bioepis’ Ontruzant, a biosimilar trastuzumab referencing Herceptin.
Number 3: In August, UnitedHealthcare indicated that it would prefer 2 oncology biosimilars in its commercial and community plans.
Number 2: In May, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.
Number 1: Finally, the US market got its first anticancer biosimilars in July when Amgen and Allergan launched biosimilar bevacizumab and trastuzumab.
To read all of these articles and more, visit centerforbiosimilars.com.